KIN-2787 is a potential treatment for BRAF class II or III alteration-positive and/or NRAS mutation-positive, metastatic or unresectable, stage IIB to IV malignant melanoma.
2022
Immunotherapy Before Targeted Therapy Improves Survival in Advanced Melanoma
Combination PD-1/CTLA-4 blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAF V600 mutant metastatic melanoma.
Novel test may predict adverse events with, recurrence after immunotherapy
An experimental test may help predict which patients with cancer may develop disease recurrence after immunotherapy treatment, according to study results published in Clinical Cancer Research.
If we know melanoma is deadly, why do we still chase the bronze dream?
I used to dream of honey-brown limbs. Sitting on the school oval at lunchtime, we’d drench our legs in sunshine in a bid for that coveted tan.